| 000 | 01537 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518003419.0 | ||
| 264 | 0 | _c20190828 | |
| 008 | 201908s 0 0 eng d | ||
| 022 | _a1543-8392 | ||
| 024 | 7 |
_a10.1021/acs.molpharmaceut.8b00880 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGu, Jie | |
| 245 | 0 | 0 |
_aThe BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma. _h[electronic resource] |
| 260 |
_bMolecular pharmaceutics _c11 2018 |
||
| 300 |
_a5387-5396 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcetanilides _xpharmacokinetics |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aHeterocyclic Compounds, 3-Ring _xpharmacokinetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aMultiple Myeloma _xdrug therapy |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aProteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aSong, Sha | |
| 700 | 1 | _aHan, Huiying | |
| 700 | 1 | _aXu, Hongxia | |
| 700 | 1 | _aFan, Gao | |
| 700 | 1 | _aQian, Chen'ao | |
| 700 | 1 | _aQiu, Yingchun | |
| 700 | 1 | _aZhou, Wenqi | |
| 700 | 1 | _aZhuang, Wenzhuo | |
| 700 | 1 | _aLi, Bingzong | |
| 773 | 0 |
_tMolecular pharmaceutics _gvol. 15 _gno. 11 _gp. 5387-5396 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1021/acs.molpharmaceut.8b00880 _zAvailable from publisher's website |
| 999 |
_c28956633 _d28956633 |
||